SAB Biotherapeutics Inc

NASDAQ:SABS   12:04:09 PM EDT
5.14
+0.36 (+7.53%)
Products, Regulatory

SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro

Published: 12/16/2021 11:48 GMT
SAB Biotherapeutics Inc (SABS) - Sab Biotherapeutics Announces Sab-185 Retains Neutralization Against Omicron Sars-cov-2 Variant in Vitro.
Sab Biotherapeutics Inc - FDA Laboratory Testing Confirms Sab-185 Neutralizes Omicron and Other Variants of Concern With in Vitro Pseudovirus Model.
Sab Biotherapeutics Inc - Sab's Targeted, Highly Potent and Fully-human Polyclonal Antibodies Continue to Show Broad Neutralization to Viral Variants.
Sab Biotherapeutics Inc - Sab-185 Currently Being Evaluated in Nih-sponsored Phase 3 Covid Trial.